ABOUT US

Founder – Robert Popovian, Pharm.D., MS

Dr. Robert Popovian is the Founder of the strategic consulting firm Conquest Advisors. He also serves as Chief Science Policy Officer at the Global Healthy Living Foundation and Senior Healthy Policy Fellow at the Progressive Policy Institute. He previously served as Vice President, U.S. Government Relations at Pfizer.

One of the country’s foremost experts on every significant facet of biopharmaceuticals and the healthcare industry, he is a recognized authority on health economics, policy, government relations, medical affairs, and strategic planning.

He is one of the select few researchers to study and publish both clinical and policy-related economic analysis as well as empirical data regarding emerging payment models in the U.S. healthcare system and for biopharmaceutical reimbursement. His insight and analysis also led to one of the first inclusions of health outcomes data regarding a biopharmaceutical labeled indication.

Dr. Popovian has published extensively on the impact of biopharmaceuticals and health policies on costs and clinical outcomes in the most prominent medical sources and media publications, including the Clinical Economics and Outcomes Research, The Oncologist, Journal of Vaccines and Vaccinations, Health Science Journal, USA Today, Managed Healthcare Executive and Morning Consult. He is also a sought-after speaker and has been invited to provide detailed presentations, briefings, and expert reviews for the U.S. Congress, dozens of state legislatures, and at conferences and medical symposiums throughout the country and around the world.

Dr. Popovian is one of the select few researchers to study and publish both clinical and policy-related economic analysis as well as empirical data regarding emerging payment models in the U.S. healthcare system and for biopharmaceutical reimbursement. His insight and analysis also led to one of the first inclusions of health outcomes data regarding a biopharmaceutical labeled indication.

As an advisor, Dr. Popovian serves on the Board of Councilors of University of Southern California School of Pharmacy, Member of the National Board of Prior Authorization Specialists Executive Committee, and Board of Advisors for ConsenSys Health.

Dr. Popovian completed his Doctorate in Pharmacy and Master of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors.  He has also completed a residency in Pharmacy Practice/Adult Internal Medicine and Infectious Diseases at the Los Angeles County-USC Hospital and a fellowship in Pharmaceutical Economics and Policy at USC.

Robert and his family have residences in Los Angeles, CA, and Washington, DC.

LinkedIn: https://www.linkedin.com/in/robert-popovian/

Twitter: @PopovianPharmD 

STRATEGIC ADVISORS

  • Elizabeth Schumacher, JD
  • CEO of Affinity Strategies

Prior to starting Affinity Strategies, Liz was Executive Director of LUGPA, a national urology subspecialty association with over 2,400 members. As a senior legislative attorney for the Americal Medical Association, Liz managed nationwide health insurance public policy development and Affordable Care Act rulemaking. While Pfizer, Liz developed and implemented strategic stakeholder engagement on key issues, including specialty tiers, access to medications, biologics, Medicare. Liz began her career at age 26 at the University of Wisconsin, where she was responsible for the third-largest academic medical research budget in the United States.

  • Peter Pitts
  • President and Co-Founder Center For Medicine in Public Interest

Peter Pitts is a Visiting Professor at the University of Paris Descartes Medical School and President of the Center for Medicine in the Public Interest. He is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration. Pitts is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines. He is the lead author of many professional peer-reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine. Pitts lives in New York City. He has given healthcare policy presentations throughout Europe, Canada, and the United States, as well as in Russia, China, Hong Kong, Taiwan, India, the Philippines, Malaysia, Saudi Arabia, Lebanon, Oman, Israel, Turkey, The United Arab Emirates, Kuwait, Qatar, Jordan, Kenya, South Africa, Egypt, Algeria, Ukraine, Thailand, Japan, Brazil, Mexico, Vietnam, Indonesia, Singapore, Panama, Costa Rica, Argentina, and Columbia. His new book is The Value Equation: A. Journey Through the Innovation Ecosystem in the Time of COVID. He is also the author of Common-Sense Healthcare for Common Sense Americans and Become Strategic or Die, widely recognized as a cutting- edge study of how leadership, in order to be successful over the long term, must be combined with strategic vision and ethical practice. He is the editor of Coincidence or Crisis, a discussion of global prescription medicine counterfeiting and Physician Disempowerment: A Transatlantic Malaise. A graduate of McGill University, he is married to Jane Mogel and has two sons.

  • Wayne Winegarden, PhD
  • Director of the Center for Medical Economics and Innovation at PRI

Dr. Winegarden is a Sr. Fellow in Business and Economics with the Pacific Research Institute, Director of the Center for Medical Economics and Innovation at PRI, and the Principal of Capitol Economic Advisors. His research explores the impacts of economic, health, pharmaceutical, fiscal, and energy policies. In addition to his Forbes column, Dr. Winegarden’s editorials have been published in outlets such as USA Today, the Wall Street Journal, Investor’s Business Daily, and the Hill. Dr. Winegarden’s consulting practice performs proprietary data analytical services that connect industry threats and opportunities to broader market dynamics and policy trends. Specific analytical services include pricing strategy analyses, product demand forecasting, industry outlooks, investment analyses, and the creation of pricing and tax models. Previously, Dr. Winegarden worked as a business economist in Hong Kong, a policy economist for U.S. based policy and trade associations, as well as adjunct economics faculty at Marymount University. Dr. Winegarden received his Ph.D. in Economics from George Mason University.

PARTNERS

Affinity Strategies is a full service nonprofit health care association management and stakeholder engagement firm. We use digital first solutions to promote transparent, efficient business practices. We partner with each client to maximize both staff and client expertise, experience, and relationships to meet our goals.